|
gptkbp:instance_of
|
gptkb:biotechnology
|
|
gptkbp:acquisition
|
Novartis assets
|
|
gptkbp:clinical_trial
|
gptkb:vaccine
Phase 3
|
|
gptkbp:collaboration
|
gptkb:Moderna
gptkb:Cure_Vac
|
|
gptkbp:focus
|
m RNA technology
|
|
gptkbp:founded
|
gptkb:2008
|
|
gptkbp:founder
|
gptkb:Uğur_Şahin
|
|
gptkbp:headquarters
|
gptkb:Mainz,_Germany
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
BNTX
|
|
gptkbp:industry
|
gptkb:pharmaceuticals
|
|
gptkbp:invention
|
m RNA technology patents
|
|
gptkbp:investment
|
$300 million from the German government
|
|
gptkbp:key_people
|
gptkb:Özlem_Türeci
|
|
gptkbp:market_cap
|
approximately $20 billion
|
|
gptkbp:notable_awards
|
gptkb:TIME_100_Most_Influential_People
|
|
gptkbp:number_of_employees
|
over 1,500
|
|
gptkbp:partnership
|
gptkb:Pfizer
gptkb:Fosun_Pharma
|
|
gptkbp:product
|
gptkb:BNT162b2
gptkb:BNT162b1
gptkb:BNT162b10
gptkb:BNT162b11
gptkb:BNT162b13
gptkb:BNT162b14
gptkb:BNT162b15
gptkb:BNT162b16
gptkb:BNT162b17
gptkb:BNT162b18
gptkb:BNT162b20
gptkb:BNT162b21
gptkb:BNT162b3
gptkb:BNT162b4
gptkb:BNT162b6
gptkb:BNT162b7
gptkb:BNT162b8
BNT162b12
BNT162b19
BNT162b22
BNT162b23
BNT162b24
BNT162b25
BNT162b26
BNT162b27
BNT162b28
BNT162b29
BNT162b30
BNT162b31
BNT162b32
BNT162b33
BNT162b34
BNT162b35
BNT162b36
BNT162b37
BNT162b38
BNT162b39
BNT162b40
BNT162b41
BNT162b42
BNT162b43
BNT162b44
BNT162b45
BNT162b46
BNT162b47
BNT162b48
BNT162b49
BNT162b5
BNT162b50
BNT162b9
|
|
gptkbp:research_areas
|
cancer immunotherapy
|
|
gptkbp:revenue
|
$18.9 billion (2021)
|
|
gptkbp:stock_symbol
|
gptkb:BNTX
|
|
gptkbp:subsidiary
|
gptkb:Bio_NTech_SE
|
|
gptkbp:type
|
gptkb:public_company
|
|
gptkbp:vaccine_type
|
gptkb:vaccine
|
|
gptkbp:website
|
www.biontech.de
|
|
gptkbp:bfsParent
|
gptkb:Bio_NTech
|
|
gptkbp:bfsLayer
|
5
|